The US Food and Drug Administration (FDA) has granted 510(k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Approval of Kerendia was based on results from the Phase III FINEARTS-HF trial, which demonstrated statistically significant ...

Dr Joseph A Hill discusses the diagnosis and management of heart failure with preserved ejection fraction (HFpEF).

Tempus AI Inc (NASDAQ:TEM) shares are trading higher Wednesday after the company announced that it received 510(k) clearance ...

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.